Core Insights - The company reported a revenue of 6.441 billion yuan for the first half of 2025, representing a year-on-year increase of 14.93% [1] - The net profit attributable to shareholders decreased by 37.00% to 701 million yuan, while the net profit excluding non-recurring gains and losses increased by 36.66% to 637 million yuan [1] - Basic earnings per share were reported at 0.3984 yuan [1] Revenue Breakdown - Laboratory services generated a revenue of 3.892 billion yuan, up 15.46% year-on-year; in Q2 2025, revenue was 2.035 billion yuan, reflecting a quarter-on-quarter increase of 9.59% [2] - The gross margin for laboratory services was 45.20%, an increase of 0.74 percentage points compared to the same period last year [2] - New orders for laboratory services increased by over 10% year-on-year during the reporting period [2] CMC Services Performance - CMC (small molecule CDMO) services achieved a revenue of 1.39 billion yuan, a year-on-year growth of 18.20%; in Q2 2025, revenue was 697 million yuan, with a quarter-on-quarter increase of 0.53% [2] - The gross margin for CMC services was 30.50%, up 2.20 percentage points from the previous year [2] - New orders for CMC services grew approximately 20% year-on-year, driven by recovering customer demand and ongoing product pipeline advancements [2]
康龙化成(300759.SZ)发布上半年业绩,归母净利润7.01亿元,下降37%